Ebrahim S. Delpassand, MD, FACNM (Nuclear Medicine)Chairman and Medical Director
Principle Investigator of FDA authorized Investigational New Drug (IND):
1. High activity In-11 Octreotide PRRT
2. Lu-177 Octreotate PRRT
3. Ga-68 Octreotate PET/CT
4. Multicenter trial of Lu-177 Octreotate therapy for midgut carcinoid sponsored by Advanced Accelerator Application (AAA).
Dr. Delpassand’s extensive experience includes the disciplines of therapeutic nuclear medicine, Peptide Receptor Radionuclide Therapy (PRRT), monoclonal antibody imaging and positron emission tomograpy (PET).